My Companies
Notification
Account
Log Out
Login
FDA approved sBLA for ILUMYA for adults with active psoriatic arthritis, expanding beyond plaque psoriasis. Approval based on Phase 3 INSPIRE-1 and INSPIRE-2 showing efficacy after two doses at 24 weeks with consistent safety. Context: resolves pending label-expansion watch for flagship innovative brand.
Sun Pharma Board To Consider Rs15,000 Crore NCD Issuance October 12
Sun Pharma Licenses Lerodalcibep From LIB Therapeutics For Ex-US China Markets
Sun Pharma Agrees U.S. MFN Pricing For Two-Year Tariff Delay
Sun Pharma Wins Favorable Lipitor Antitrust Ruling In US Appeal